Companies: 10,795·Total market cap: $144.5T
Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKANASDAQHealthcare● Active
$65.61
+$1.55(+2.42%)
Market Cap$2.5B
P/E Ratio
52W High$91
52W Low$10.77
Overview

Oruka Therapeutics, Inc. (ORKA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ORKA · as of Jun 9, 2026

Key Statistics

EPS (TTM)orka eps ttm · orka earnings per shareEarnings history
PE Ratio (TTM)orka pe ratio ttm · orka price to earningsPE Ratio deep dive
Revenue (TTM)orka revenue ttm · orka annual revenueFull revenue history
Dividend YieldNo Dividenddoes orka pay dividends · orka dividend yieldDividend history
Shares Outstandingorka shares outstanding · orka floatShares outstanding history
Next EarningsTBAorka earnings date · orka next earningsEarnings history

About Oruka Therapeutics, Inc.

CEOLawrence Otto Klein
IPO DateAug 8, 1997
Employees28
CountryUS

Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along …

what is oruka therapeutics, inc. · orka stock overview · oruka therapeutics, inc. company profile · who is oruka therapeutics, inc. ceo · orka NASDAQ · oruka therapeutics, inc. headquarters · oruka therapeutics, inc. business segments

About Stock Overview & Key Data

Oruka Therapeutics, Inc. (ORKA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 8, 1997. As of the latest trading session, ORKA stock price is $65.61, with a market capitalization of $2.5B. The stock has returned — over the past 12 months and — year-to-date.

Frequently Asked Questions

As of the latest trading session, Oruka Therapeutics, Inc. (ORKA) stock price is $65.61. The stock is traded on NASDAQ under the ticker symbol ORKA. The 52-week range is $10.77 – $91.00.

ORKA stock priceORKA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice